Apart from its involvement in autoimmune disorders, IL‐17A emerges as a key player in cancer, with notable implications in pancreatic ductal adenocarcinoma (PDAC), where IL‐17A/IL‐17RA signaling profoundly impacts various facets of tumor biology including cell proliferation, growth, progression, microenvironmental remodeling, and resistance to treatment, all mediated by the inflammatory milieu within the tumor microenvironment.1, 4, 5. This evidence concerns the gene IL17RA and neoplasm.